Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 1 000 UNITS IN SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER versus MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 1 000 UNITS IN SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER versus MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER.
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III, causing a conformational change that accelerates the inactivation of thrombin (factor IIa) and activated factor X (factor Xa), thereby inhibiting coagulation.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Adult: IV bolus 5,000 units followed by continuous IV infusion at 1,000 units/hour (25,000-40,000 units/24h) titrated to aPTT 1.5-2.5 times control. Subcutaneous: 5,000 units every 8-12 hours.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
None Documented
None Documented
Terminal elimination half-life is dose-dependent: 0.5–1.5 hours after intravenous administration of 100 U/kg, increasing to 1.5–2.5 hours after 200 U/kg, and up to 3–6 hours after 400 U/kg. Clinically, the anticoagulant effect (aPTT) has a half-life of approximately 1–2 hours, and this is used for dosing adjustments.
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
Renal: Heparin is primarily cleared by the reticuloendothelial system and the liver via desulfation and depolymerization, with metabolites excreted in urine. Only about 50% of an administered dose is excreted unchanged in urine at therapeutic doses; the remainder is metabolized. Biliary/fecal excretion is minimal.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Category A/B
Category C
Electrolyte
Electrolyte